CJC-1295 DAC 5 mg

POPULAR 2026 | RESEARCH LIBRARY

CJC-1295 DAC

A plain-language research page on identity, mechanism, evidence, uncertainties and South African context.

Contents

Important information · Identity · Research questions · Mechanism · Evidence · Regulatory context · Comparison · Risks · Common questions · Research updates · Sources

Important information and disclaimer

This page is for education about published research. It does not advertise, offer or recommend CJC-1295 DAC and does not provide dosing or self-treatment advice. Inclusion in an image concept pack is not evidence of a registered product, proven benefit or permission to market it.

An online label or certificate cannot alone establish identity, purity, sterility, strength, stability or suitability for human use. Anyone with serious symptoms should obtain clinical assessment rather than rely on an experimental peptide.

What is CJC-1295 DAC?

CJC-1295 with DAC is a long-acting analogue of growth-hormone-releasing hormone. The drug-affinity-complex modification promotes prolonged binding to circulating albumin. Product names that omit or misuse 'DAC' can refer to materially different molecules.

Identity distinctions that prevent confusion

CJC-1295 DAC is not the same as a short-acting GHRH fragment often marketed as 'CJC-1295 no DAC' or 'modified GRF 1-29'. A similar nickname, peptide family or visual label is insufficient to show chemical identity. Documentation must refer to the actual material and formulation under consideration.

What is CJC-1295 DAC researched for?

Early human work tested duration of exposure and changes in growth hormone and IGF-1 in healthy volunteers. This is endocrine pharmacology, not evidence of an approved treatment for ageing, fat loss or muscle gain.

Other potential uses if future research confirms them

A legitimate therapeutic programme would need a specific disease, dose-ranging, long-term safety, and patient outcomes rather than simply higher IGF-1.

A future indication requires more than a plausible molecular pathway. Researchers need a defined patient group, an appropriate comparator, outcomes that matter to patients, and follow-up long enough to reveal important harms. The amount printed on a draft vial image answers none of those questions.

How might CJC-1295 DAC work?

It stimulates the GHRH receptor and can sustain increased GH and IGF-1 signalling over several days. Endocrine markers do not establish net clinical benefit.

Mechanistic work can identify a testable pathway, but it cannot specify a clinically useful route or prove that a laboratory signal will survive the complexity of a human disease. Exposure and target engagement should be measured in a study rather than inferred from a supplier label.

What has the evidence found?

A human study demonstrated prolonged stimulation of GH and IGF-1; another examined whether pulsatile secretion persisted. These were small physiology studies with limited ability to assess rare or long-term harms.

Evidence from cells, animals, hormone measurements or small clinical studies must be judged separately. A promising mechanism is a reason to investigate a question, not a demonstration of clinical efficacy.

How strong is the evidence?

The strongest evidence depends on the specific claim. A human pharmacology experiment may prove a short-term hormone response but not a health benefit; a small patient trial may identify an early signal but miss rare harms. Animal and cell findings are valuable for choosing the next experiment, while a well-designed clinical trial is needed for a treatment claim.

Current status and South African context

This page does not assert South African registration or a particular legal supply route. Before any public product listing, check the exact formulation, manufacturer and indication against current SAHPRA records and obtain professional regulatory review. SAHPRA warns about unregistered peptide products sold through informal channels.

How CJC-1295 DAC compares with nearby concepts

CJC-1295 DAC is not the same as a short-acting GHRH fragment often marketed as 'CJC-1295 no DAC' or 'modified GRF 1-29'.

Risks and uncertainties

Prolonged endocrine stimulation may be particularly relevant to glucose control, fluid retention and certain tumour histories. Mislabelled DAC status changes the expected exposure profile.

Risk has at least two parts: the biological effects of the molecule, and the quality of a particular preparation. A published study using controlled material does not verify an unrelated online vial. For any injectable product, identity, sterility, endotoxin control and storage are distinct questions; a simple purity figure does not settle them.

Treatment and measurement safeguards

A clinician or investigator would first define the condition, baseline measurements and relevant standard treatment. Outcomes would be measured prospectively and adverse events recorded. The public research page should avoid conversion charts, injection instructions or promises about results, and should say when an established treatment is available.

Common questions

Is CJC-1295 DAC a proven treatment?

Not for the broad claims often attached to its name. The evidence described here must be read for the exact indication, route and measured outcome.

Does a mechanism mean it works in people?

No. A receptor, cell or animal result supports a hypothesis; clinical benefit and safety require human testing.

Does the pictured strength validate a product?

No. The draft strength is an image identifier and must be checked against actual specifications before a listing.

Can two similar peptide names be substituted?

CJC-1295 DAC is not the same as a short-acting GHRH fragment often marketed as 'CJC-1295 no DAC' or 'modified GRF 1-29'.

Does a certificate or CAS number prove suitability for human use?

No. Such details may help identify a material, but they do not by themselves establish formulation, sterility, stability, authorisation or therapeutic value.

What would change this page?

A rigorous new trial, a corrected publication, a regulator decision or verified product specification could change a specific conclusion.

Join for research and regulatory updates

Readers who want to track CJC-1295 DAC can set a periodic alert for its exact name plus 'clinical trial', 'randomised', 'publication' and 'SAHPRA'. An AI reminder should bring back the study or regulator link, publication date, population, outcome and limitations. Verify the source before treating an alert as a change in evidence.

Sources and further reading

Long-acting human study: https://pubmed.ncbi.nlm.nih.gov/16352683/

GH pulsatility study: https://pubmed.ncbi.nlm.nih.gov/17018654/

SAHPRA public peptide information: https://www.sahpra.org.za/peptide-products-public-information/

Research review date: 26 September 2026. Verify current trial and regulatory status before publication.